BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Alabbad S, AlGaeed M, Sikorski P, Kaminski HJ. Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs 2020;34:557-66. [PMID: 32915379 DOI: 10.1007/s40259-020-00443-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ 2022;:1-16. [PMID: 35020547 DOI: 10.1080/13696998.2022.2027706] [Reference Citation Analysis]
3 Yeter HH, Derici U, Arinsoy T, Altok K, Erten Y, Guz G. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. Rom J Intern Med 2021. [PMID: 34449174 DOI: 10.2478/rjim-2021-0034] [Reference Citation Analysis]
4 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
5 Coelho Júnior JL, Israel KCP, Machado CEE, Muniz MPR, Gatto GC, Barros FHS, Cunha KA, de Lacerda MVG, Neves PDMM, Silva GEB. Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. PLoS Negl Trop Dis 2021;15:e0009790. [PMID: 34648498 DOI: 10.1371/journal.pntd.0009790] [Reference Citation Analysis]
6 Ghosh K, Ghosh K. Monoclonal antibodies used for the management of haematological disorders. Expert Rev Hematol 2022. [PMID: 35504000 DOI: 10.1080/17474086.2022.2073213] [Reference Citation Analysis]
7 Vilardouro AS, Cachão J, Rodrigues M, Durão F, Costa-Reis P, Sandes AR, Silva JED, Boto L, Stone R. Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit. J Bras Nefrol 2022:S0101-28002022005021402. [PMID: 35385571 DOI: 10.1590/2175-8239-JBN-2021-0206] [Reference Citation Analysis]
8 Ahmadpoor P, Aglae C, Cariou S, Pambrun E, Renaud S, Garo F, Darmon R, Schultz C, Prelipcean C, Reboul P, Moranne O. Physiological role of plasma and its components and the clinical implications of different methods of apheresis: A narrative review. Ther Apher Dial 2021;25:262-72. [PMID: 32710797 DOI: 10.1111/1744-9987.13567] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]